YB-200 / Ymmunobio - LARVOL DELTA

Ymmunobio to Present at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT) (BioPharma Dive) - "Ymmunobio...has been selected to present findings from its lead asset YB-200 at the 20th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) on May 4, 2023....'We look forward to sharing results from our research into the mechanism of action of our monoclonal antibody YB-200'."

Preclinical • Oncology

FDA Grants Orphan Drug Designation to Ymmunobio's CEACAM Antibody for the Treatment of Liver Cancer (PRNewswire) - "Ymmunobio...announced today that it has been granted Orphan Drug Designation (ODD) by the US Food & Drug Administration (FDA) for YB-200, a CEACAM1/5 antibody it is studying for the treatment of hepatocellular carcinoma (HCC)."

Orphan drug • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Novel, immune agonistic CEACAM1/5 antibody (YB-200) demonstrates anti-tumor efficacy and significantly increases B-cell response in syngeneic liver Hepa1-6 tumor microenvironment (SITC 2022) - "Ethics Approval This animal study has been approved by the Ethics Committee for Animal Experimentation and is registered by the regional board Freiburg, Germany. Mice were handled according to the German animal welfare law and the GV-SOLAS guidelines."

Biomarker • Clinical • Tumor microenvironment • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • CD4 • CEACAM1 • CEACAM5